Drugs / PF-07293893
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06413693 | May → Aug 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06177457 | Dec 2023 → Dec 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05907395 | Aug 2023 → Mar 2024 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07293893 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06177457 ↗ |
| Route | Oral | “PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.” NCT05907395 ↗ |